Trials / Withdrawn
WithdrawnNCT04868045
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether people who have had thyroid cancer develop resistance to treatment with thyroid hormones after having received high doses of thyroid drugs for many years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thyrotropin Releasing Hormone (TRH) | TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5. |
| DRUG | levothyroxine | Patients maintenance dose of levothyroxine will be taken throughout the study. On Day 1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning. |
| OTHER | Hypothyroidism QOL questionnaire | Administer standardized Hypothyroidism QOL questionnaire. |
Timeline
- Start date
- 2021-04-27
- Primary completion
- 2023-02-15
- Completion
- 2023-02-15
- First posted
- 2021-04-30
- Last updated
- 2023-02-21
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04868045. Inclusion in this directory is not an endorsement.